Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer.

Journal: Oncology research •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Liu X, Hua B, Xia Y, et al. (2026). "Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer.". Oncology research. https://doi.org/10.32604/or.2026.088774